Searching for new solutions in diseases of central nervous system 1600-OG-EN-SFNSID

1. To present the pathophysiology of neurodegenerative diseases and the clinical symptoms.
2. Presentation of currently used therapies and summary of guidelines for their use.
3. Literature review on new therapeutic perspectives in selected conditions.

Całkowity nakład pracy studenta

Contact hours with teacher: - participation in seminars - 20 hrs - consultations - 5 hrs Self-study hours: - preparation for seminars - 10hrs - reading literature - 10 hrs - preparation for examination - 5 hrs Altogether: 50 hrs (2 ECTS)

Efekty uczenia się - wiedza

W1: causes, symptoms, and principles of diagnosis and treatment of the most common nervous system diseases E.W14 W2: basic concepts related to the pathogenesis of mental disorders E.W15 W3: basic methods of statistical analysis used in population studies and diagnostic assays B.W27

Efekty uczenia się - umiejętności

U1: select drugs and their appropriate doses in order to correct pathological changes in the organism and in individual organs C.U14 U2: perform an analysis of possible adverse effects of individual drugs and drug interactions E.U17 U3: in case of ineffectiveness of or contraindications to standard therapy, propose the individualization of currently accepted therapeutic guidelines and other treatment methods E.U17

Efekty uczenia się - kompetencje społeczne

K1: ability to use objective sources of information; K_K01 K2: ability to formulate opinions based on own assessment and observation; K_K.10

Metody dydaktyczne

- informative lecture - participatory lecture

Rodzaj przedmiotu

przedmiot fakultatywny

Wymagania wstępne

none

Koordynatorzy przedmiotu

Michał Wiciński

Kryteria oceniania

Assessment methods:
- a final essay

Assessment criteria:
- non-graded credit

Praktyki zawodowe

not applicable

Literatura

1. Farmakologia i toksykologia E. Mutschlera PZWL
2. Gitler, A. D., Dhillon, P., & Shorter, J. (2017). Neurodegenerative disease: models, mechanisms, and a new hope.
3. Aprahamian, I., Stella, F., & Forlenza, O. V. (2013). New treatment strategies for Alzheimer's disease: is there a hope? The Indian journal of medical research, 138(4), 449.
4. Millington, C., Sonego, S., Karunaweera, N., Rangel, A., Aldrich-Wright, J. R., Campbell, I. L., ... & Münch, G. (2014). Chronic neuroinflammation in Alzheimer’s disease: new perspectives on animal models and promising candidate drugs. BioMed research international, 2014.
5. Li, L., & Hölscher, C. (2007). Common pathological processes in Alzheimer disease and type 2 diabetes: a review. Brain research reviews, 56(2), 384-402.
6. Pazos, M. R., Nunez, E., Benito, C., Tolon, R. M., & Romero, J. (2004). Role of the endocannabinoid system in Alzheimer's disease: new perspectives. Life sciences, 75(16), 1907-1915.
7. Wiciński, M., Domanowska, A., Wódkiewicz, E., & Malinowski, B. (2020). Neuroprotective Properties of Resveratrol and Its Derivatives—Influence on Potential Mechanisms Leading to the Development of Alzheimer’s Disease. International Journal of Molecular Sciences, 21(8), 2749.
8. Wiciński, M., Wódkiewicz, E., Słupski, M., Walczak, M., Socha, M., Malinowski, B., & Pawlak-Osińska, K. (2018). Neuroprotective activity of sitagliptin via reduction of neuroinflammation beyond the incretin effect: Focus on Alzheimer’s disease. BioMed research international, 2018.

Więcej informacji

Dodatkowe informacje (np. o kalendarzu rejestracji, prowadzących zajęcia, lokalizacji i terminach zajęć) mogą być dostępne w serwisie USOSweb:

Strona przedmiotu 1600-OG-EN-SFNSID w USOSweb